DOI QR코드

DOI QR Code

Comparisons of Curative and Side Effects of Chemoradiotherapy among Xinjiang Han, Uigur and Kazakh Esophageal Carcinoma Patients

  • Zhang, Li (Cancer Center of The First Affiliated Hospital of Xinjiang Medical University) ;
  • Ma, Li-Li (Cancer Center of The First Affiliated Hospital of Xinjiang Medical University) ;
  • Zhang, Jian-Qing (Cancer Center of The First Affiliated Hospital of Xinjiang Medical University) ;
  • Yang, Mei (Cancer Center of The First Affiliated Hospital of Xinjiang Medical University) ;
  • Xun, Tu-Er (Cancer Center of The First Affiliated Hospital of Xinjiang Medical University) ;
  • Li, Ai (Cancer Center of The First Affiliated Hospital of Xinjiang Medical University)
  • 발행 : 2012.01.31

초록

Objective: This study aimed to explore the differences in the curative and side effects of chemoradiotherapy on esophageal cancer (EC) among Xinjiang Han, Uigur and Kazakh patients. Methods: 170 patients with IIA stage-IV of esophageal squamous cell carcinoma were analyzed retrospectively. Based on different nationalities, they were divided into the Han, Uigur and Kazakh groups. The 1-, 2- and 3-year survival rates, incidence of the side effects (including hematological toxicities, radioactive esophagitis and percutaneous reactions) and application of antibiotics and harmonics were compared among the groups. There was no significant difference in the short-term curative effects among the Han, Uigur and Kazakh groups. The 1- 2- and 3-year survival rates of the three groups were 84%, 40%, 26%; 78%, 27%, 18%; and 60%, 21%, 12% ($x^2$=14.497, P<0.05). The incidence rate of hamatological toxicity ${\geq}$Grade 2 in the Kazakh group was significantly lower than that in the Han or Uigur group. Results: The incidence rates of radioactive esophagitis and percutaneous reactions Grade 2 in the Han group were significantly higher than those in the Uigur or Kazakh group. There was no significant difference in the types of applied antibiotics among the groups, but there were significant differences in the days of antibiotic application and proportion of patients receiving harmonics between the Hans and either of other groups. Conclusion: Chemoradiotherapy shows a better effect in the long-term survival rate among Han EC patients compared with Uigur or Kazakh EC patients. Uigur and Kazakh patients show a better tolerance to the side effects of chemoradiotherapy compared with Hans.

키워드

참고문헌

  1. Cooper JS, Uo MD, Herskovic A, et al (1999). Chemoradiotherapy of locally advanced esophageal cancer: long term follow -up of a prospective randomized trial (RTOG 8501). Radiat Therapy oncol Group. JAMA, 281, 1623-7. https://doi.org/10.1001/jama.281.17.1623
  2. Cox JD, Stetz J, Pajak TF (1995). Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys, 31, 1341-6. https://doi.org/10.1016/0360-3016(95)00060-C
  3. Dillman RO, Herndon J, Seagren SL, et al (1996). Improved survival in stage III non-small cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst, 88, 1210-5. https://doi.org/10.1093/jnci/88.17.1210
  4. Doornum V, Korse CM, Buning-Kager JC, et al (2003). Reactivity to human papillomavirus type 16 L1virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extra-genital sites. Br J Cancer, 88, 1095-100. https://doi.org/10.1038/sj.bjc.6600870
  5. Fu KK, Pajak TF, Trotti A, et al (2000). A radiation therapy oncology group (RTPOG) phase III randomized study to compare hyper-fractionation and two variants of accelerated fractionation to standard fractionation radio-therapy for head-and neck squamous cell carcinomas:first report of RTOG 9003. Int J Radiat Oncol Biol Phys, 48, 7-16. https://doi.org/10.1016/S0360-3016(00)00663-5
  6. Jemal A, Clegg LX, Ward E, et al (2004). Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer, 101, 3-27. https://doi.org/10.1002/cncr.20288
  7. Jordan SD, Poole CJ, Archer VR, et al (2003). A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens. Cancer Chemother Pharmacol, 52, 113-8. https://doi.org/10.1007/s00280-003-0634-8
  8. Kleinberg L, Knisely JP, Hritmiller R, et al (2003). Mater survival results with preoperative cisplatin, protracted infusion 5-fluorouracil,and44-GY radiotherapy for esophageal cancer. Int J Radiat Oncol Biol, 56, 358-34.
  9. Liu Z, Feng JG, Tuersun A, et al (2011). Proteomic identification of differentially-expressed proteins in esophageal cancer in three ethnic groups in Xinjiang. Mol Biol Rep, 38, 3261-9. https://doi.org/10.1007/s11033-010-0586-0
  10. Ma HB, Zhang XZ, Wang XJ, et al (2010). Effects of threedimensional conformal radiotherapy on the esophageal carcinoma. Chinese-German J Clin Oncol, 9, 579-82. https://doi.org/10.1007/s10330-010-0643-0
  11. Mariette C, Piessen G, Triboulet JP (2007). Therapeutic strategies in esophageal carcinoma: role of surgery and other modalities. Lanett Oncol, 8, 545-53. https://doi.org/10.1016/S1470-2045(07)70172-9
  12. Neuner G, Patel A, Suntharalingam M (2009). Chemoradiotherapy for Esophageal Cancer. Gastrointest Cancer Res, 3, 57-65.
  13. Park J, Ahn YC, Kim H, et al (2003). A phase II trial of concurrent chemo-radiation therapy followed by consolidation chemotherapy with oral etopo-side and cisplatin for locally advanced inoperable non-small cell lung cancers. Lung Cancer, 42, 227-35. https://doi.org/10.1016/S0169-5002(03)00282-4
  14. Parkin D, Bray F, Ferlay J, et al (2005). Global Cancer Statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  15. Si HX, Tsao SW, Poon CS, et al (2003). Viral load of HPV in esophageal squamous cell carcinoma. Int J Cancer, 103, 496-500. https://doi.org/10.1002/ijc.10865
  16. Slvain C, Barrioz T, Besson I, et al (1993). Treatment and longterm outcome of chronic radiation esophagitis after radiation therapy for head and neck tumors. Diq Dis Sci, 38, 927-31. https://doi.org/10.1007/BF01295922
  17. Withers HR (1992). Biologic basis of radiation therapy. In: Perez CA, Brady LW, editors. Principles and practice of radiation herapy (2nd ed), JB Lippincot. Philadelphia, pp, 64-98,
  18. Wong RK, Malthaner R (2006). Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev, 1, CD002092.
  19. Zeng T, MaY, Xu L, et al (2011). A 1: 2 Case-control Study of Tap2/HLA-DR9 Gene Polymorphism with Esophageal Cancer in Kazakh. Cancer Res Prev Treat, 38, 210-3.
  20. Zhang L, Li Q, Zhang JQ, et al (2011). Investigation and analysis on quality of life and related impact parameters of Han and minority nationality patients with advanced esophageal carcinoma undergoing radiotherapy in Xinjiang. J Chin Radiat Oncol, 4, 295-6.
  21. Zhou SM, SheyhidinI, Yang T, et al (2009). Relationship between human papillomavirus 16 and esophageal squamous cell carcinoma in Uygur population in Xinjiang Uygur Autonomous Region. World Chin J Digestol, 17, 3214-7. https://doi.org/10.11569/wcjd.v17.i31.3214
  22. Zou X, Lu F, Zhang X, et al (2002).Characteristics of esophageal cancer mortality, in China, 1990/1992. Bull Chin Cancer, 11, P446-9.

피인용 문헌

  1. TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6991